The ORF5-encoded major envelope glycoprotein (GP 5 ) of porcine reproductive and respiratory syndrome virus (PRRSV) is one of the three major structural proteins of this virus. While some porcine convalescent sera and monoclonal antibodies directed against GP 4 and GP 5 have the capacity to neutralize the virus in vitro, the protein specificity of porcine neutralizing sera has not yet been established. DNA immunization with a plasmid encoding GP 5 of PRRSV, under the control of a human cytomegalovirus promoter, induced anti-GP 5 -specific neutralizing antibodies in pigs and BALB/c mice. The GP 5 protein specificity of neutralizing sera was confirmed by immunoblotting and ELISA. Peripheral blood mononuclear cells obtained from DNA-vaccinated pigs underwent blastogenic trans-
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is a disease found in swine farms worldwide and it is characterized by reproductive failure such as late-term abortions in sows and by respiratory illness and mortality in young pigs (Dea et al., 1992 ; Goyal, 1993) . The nucleotide sequence, genomic organization and replication strategy of porcine reproductive and respiratory syndrome virus (PRRSV) are related to those of a group of small, enveloped, positive-stranded RNA viruses including murine lactate dehydrogenase elevating virus (LDV), equine arteritis virus (EAV) and simian haemorrhagic fever virus, which are presently classified within the family Arteriviridae, order Nidovirales (Cavanagh, 1997) . The genome of PRRSV is about 15 kb in length and contains eight open reading frames (ORFs). ORFs 1a and 1b, situated at the 5h end of the genome, represent nearly 75 % of the viral genome and Author for correspondence : Serge Dea.
Fax j1 514 686 5627. e-mail SergeIDea!IAF.UQUEBEC.CA formation in the presence of E. coli-expressed recombinant ORF5-encoded protein, indicating the specificity of the cellular immune response to GP 5 . Following a massive intratracheal challenge with the virulent IAF-Klop strain of PRRSV, DNA-vaccinated pigs were protected from generalized viraemia and the development of typical macroscopic lung lesions that were observed in unvaccinated, viruschallenged controls, as well as in pigs that were immunized with E. coli-expressed GST-ORF5 recombinant fusion protein. Interstitial pneumonitis and broncho-alveolitis were remarkably milder in DNA-vaccinated animals. These results suggest that the GP 5 of PRRSV is a good candidate for a subunit recombinant-type vaccine.
code for proteins with apparent replicase and polymerase activities (Meulenberg et al., 1993) . Six putative structural proteins have been identified and assigned to distinct smaller ORFs, ORFs 2-7, located at the 3h end of the genome (Mardassi et al., 1995 (Mardassi et al., , 1996 Meulenberg et al., 1993) . The virion contains three major structural proteins, a 25 kDa envelope glycoprotein (GP & ), an 18-19 kDa unglycosylated membrane protein (M), and a 15 kDa nucleocapsid (N) protein, encoded by ORFs 5, 6 and 7, respectively. In addition, the translation products of ORFs 2, 3 and 4, with respective apparent molecular masses of 30, 45 and 31 kDa, also have characteristics of membrane-associated glycoproteins (Mardassi et al., 1995 ; Meulenberg et al., 1995) . Recent findings on the characterization of structural proteins of Lelystad virus, the European prototype strain of PRRSV, indicate that expression products of the above ORFs, designated GP # , GP $ and GP % , respectively, are incorporated into virus particles (Meulenberg & Petersen-Den Besten, 1996 ; Van Nieuwstadt et al., 1996) . While pigs develop neutralizing antibodies 4-6 weeks after exposure to virus, the protein specificity of such neutralizing 0001-5295 # 1998 SGM
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antibodies is yet to be established. Monoclonal antibodies (MAbs) specific to GP % of PRRSV neutralize the virus in vitro (Meulenberg et al., 1997 ; Van Nieuwstadt et al., 1996) but the reactivity of convalescent pig sera with this viral protein is not constant (Meulenberg et al., 1995 (Meulenberg et al., , 1997 . The ORF4 gene of a North American strain of PRRSV has been also cloned and expressed in E. coli (Kwang et al., 1994) . Only 65 % of PRRSVpositive sera obtained from affected pig farms reacted positively by immunoblotting with the recombinant ORF4-encoded protein. Therefore, the involvement of ORF4-encoded protein in inducing neutralizing antibodies following PRRSV infection is yet to be determined.
We have recently established that MAbs derived from spleen cells of mice immunized with recombinant ORF5-encoded protein expressed in E. coli neutralized PRRSV in vitro and therefore, as for other arteriviruses, notably EAV (Balasuriya et al., 1993) and LDV (Coutelier et al., 1988) , the ORF5-encoded glycoprotein of PRRSV is associated with neutralizing epitopes. However, results of our previous studies indicated that immunization with the same antigenic preparation did not induce neutralizing antibodies in pigs (Loemba et al., 1996) . The purpose of the present work was to study the immunogenicity of the GP & of PRRSV in pigs and to establish if animals exposed to the native form of the protein by means of DNA immunization develop specific neutralizing and protecting antibodies.
Methods
Experimental animals. Twelve crossbred F1 (Landracei Yorkshire) SPF piglets weaned at 3 weeks of age were obtained from a breeding farm in the province of Quebec, Canada. The breeding stock and piglets were tested and proven to be seronegative for PRRSV, encephalomyocarditis virus, porcine parvovirus, haemagglutinating encephalomyelitis virus, transmissible gastroenteritis virus and Mycoplasma hyopneumoniae. The piglets used in this study were from two different litters and were randomly divided into four experimental groups (Table  1) . Each group of three piglets were allocated to separate isolation rooms in facilities equipped with a microorganism-free, filtered in-flowing and out-flowing air system. They were fed commercial food and water ad libitum.
Six-week-old female BALB\c and CD-1 mice were purchased from Charles River Laboratories and separated in groups of five mice per cage ; cages were equipped with individual filtered air channels.
Virus and challenge. The Quebec cytopathic strain IAF-Klop (Mardassi et al., 1995) used in this study was initially isolated from an acute case of PRRS and propagated in MARC-145 cells, a clone of MA-104 cells highly permissive to PRRSV (Kim et al., 1993) , graciously provided by J. Kwang (US Meat Animal Research Centre, USDA, Agricultural Research Service, Clay Centre, NE, USA). Virus titration was done by end-point dilution using immunoperoxidase on monolayer assay (IPMA) (Wensvoort et al., 1991) and virus titres were expressed as tissue culture infective dose 50 (TCID &! ) per ml, as previously described (Dea et al., 1992) . In order to verify the virulence of the virus strain and eliminate MARC-145 cellular proteins that may be co-purified with the virus, PRRSV strain IAF-Klop was subjected to one passage on primary cultures of porcine alveolar macrophages (PAMs), followed by two successive in vivo passages in pigs. The animals used for providing PAMs and for virus adaptation were obtained from the same farm and were treated and reared under the same conditions, as mentioned above. Piglets used for in vivo passages received 10 ml cell culture supernatant, adjusted to 10' TCID &! virus\ml, via intratracheal inoculation. On the seventh day post-inoculation (p.i.), when respiratory distress became evident, the piglets were euthanized and their lungs were aseptically collected and homogenized in RPMI medium supplemented with 200 U\ml penicillin, 200 µg\ml streptomycin and 50 µg\ml gentamycin. Each challenged piglet received 10 ml clarified 5 % lung homogenate in sterile RPMI medium via intratracheal injection corresponding to an infectious dose of 5i10& TCID &! of virus, as established by back titration. The inoculum was further tested for the presence of porcine pathogens as described above and no agent other than PRRSV could be isolated.
Plasmids and recombinant proteins. Viral RNA was extracted from PRRSV-infected MARC-145 cells as previously described (Mardassi et al., 1995) . The ORF5-encoding region was amplified by RT-PCR, cloned in the pGEX-4T1 plasmid (Pharmacia) ; a recombinant fusion protein consisting of glutathione S-transferase (GST) joined to the N terminus of the ORF5 protein (GST-ORF5) was expressed in E. coli and purified by affinity chromatography on a glutathione-Sepharose column as previously described . Subsequent SDS-PAGE analysis of the purified protein confirmed that no contaminating bacterial proteins were present in the purified recombinant fusion protein (data not shown). Plasmidic DNA was purified from bacterial lysates by anion exchange chromatography on a hydroxyapatite column (QIAGEN) and then precipitated with isopropanol. This procedure effectively eliminated bacterial protein contaminants. The same amplification product was cloned in the pET21a plasmid (Novagen) to produce a recombinant protein in E. coli consisting of the ORF5-encoded protein fused at the C terminus to six histidine residues (ORF5-pH). The ORF5 coding region was further cloned into the HindIII and XbaI cloning sites of the eukaryotic expression vector pRc\CMV (Invitrogen), downstream of the human cytomegalovirus (HCMV) promoter, to produce pRc\CMV5. The sequences of the oligonucleotide primers used for the latter amplification were as follows : ETS5 (forward primer), 5h AAGCTTGC-CGCCGCCATGTTGGGGAAATGCTTGACC 3h, which comprises the first ATG codon of the ORF5 gene downstream of a Kozak motif for initiation of translation in vertebrates (Kozak, 1987) ; and ETR5 (reverse primer), 5h TCTAGAGGCAAAAGTCATCTAGGG 3h, which comprises the C-terminal stop codon of the viral gene. The nucleotide sequence accession number (EMBL\GenBank\DDBJ libraries) of IAF-Klop strain is U64928. For directional cloning, HindIII and XbaI restriction sites were added at the 5h ends of the sense and antisense oligonucleotide primers, respectively. Both strands of pRc\CMV5 were sequenced in an Automated Laser Fluorescent DNA sequencer (Pharmacia LKB) in order to confirm that no errors were introduced as a result of PCR amplification.
Transient expression of the GP 5 glycoprotein. Ex vivo expression of the pRc\CMV5 construct was tested in transient expression experiments in COS7 and 293 cells maintained as confluent monolayers. Cells in 6 cm tissue culture plates were transfected with 15 µg plasmid DNA by calcium phosphate co-precipitation (Graham & Van der Eb, 1973) . For indirect immunofluorescence (IIF), cells were incubated at 37 mC and fixed with 80 % cold acetone for 20 min at 4 mC at various times (18-72 h) post-transfection. The monolayers were then reacted for 30 min with anti-ORF5 rabbit monospecific hyperimmune serum (Mardassi et al., 1996) and the immune reaction was determined following incubation with fluorescein-conjugated goat anti-rabbit Ig (Boehringer Mannheim), as previously described (Loemba et al., 1996) . † ELISA : reciprocal of highest serum dilution reacting with the recombinant ORF5-pH expressed in E. coli. IIF : reciprocal of highest serum dilution at which specific cytoplasmic fluorescence was observed in PRRSV-infected MARC-145 cells. VN : reciprocal of highest serum dilution which inhibited 100 % of CPE and expression of viral N protein in PRRSV (strain IAF-Klop) infected MARC-145 cells stained by IPMA. ‡ Groups of five mice or three piglets were immunized by pRc\CMV5 plasmid or GST-ORF5 expressed in E. coli on the mentioned days. Blood samples were collected from retro-orbital vein of mice or anterior vena cava of pigs prior to each immunization. § Pigs were challenged with 5i10& TCID &! by intratracheal inoculation. R Sample collection only.
Mice immunization schedule.
In vivo expression of pRc\CMV5 was verified by immunizing groups of five CD-1 or BALB\c mice with 50 µg pRc\CMV5 diluted in 50 µl PBS ; the DNA was injected into the tibialis cranialis muscle with a 27 gauge needle. The mice were boosted twice with the same quantities of DNA at 2 week intervals. Control mice received the same amounts of parental pRc\CMV vector via an identical route and frequency or three intraperitoneal doses of 50 µg GST-ORF5 in Freund's complete or incomplete adjuvant.
Pig immunization schedule. Groups of three piglets were injected three times at 2 week intervals with 100 µg pRc\CMV5 diluted in 0n5 ml PBS. Two-thirds of the volume was injected, using a 26 gauge needle, into the tibialis cranialis muscle of the right leg and one-third was intradermally administered into the dorsal surface of the ear. Control piglets received either 100 µg parental vector via an identical route and frequency or 300 µg GST-ORF5.
Virus neutralization and serological tests.
Mouse and pig sera were tested for the presence of specific anti-GP & antibodies by virus neutralization (VN), IIF, ELISA and Western immunoblotting (WB) tests. The VN test was performed in triplicate with 100 µl serial dilutions of heat-inactivated (56 mC for 45 min) test sera, incubated for 60 min at 37 mC in the presence of 100 TCID &! of the virus in DMEM ; the mixtures were put in contact with confluent monolayers of MARC-145 cells that had been seeded in 96-well microtitration plates 48-72 h earlier. Cell monolayers were incubated at 37 mC in a humidified atmosphere containing 5 % CO # , and observed daily for up to 5 days for the appearance of cytopathic effects (CPE). The monolayers were then fixed with a solution of 80 % methanol containing 0n05 % H # O # , and tested for expression of the PRRSV nucleocapsid protein by IPMA (Wensvoort et al., 1991) , using the N protein-specific MAb IAF-K8 . The immune reaction was determined following subsequent incubation with peroxidase-labelled goat anti-mouse IgG (Boehringer Mannheim). Neutralizing titres were expressed as the reciprocal of the highest dilution which completely inhibited expression of the viral N protein. IIF was performed on PRRSV-infected and acetone-fixed MARC-145 cells as previously described (Loemba et al., 1996) . Indirect ELISA was essentially performed as previously described with minor modifications. Gel-purified ORF5-pH protein (0n1 µg protein per well) in 0n05 M sodium carbonate buffer, pH 9n6, was used to coat flat-bottomed microtitration plates and peroxidase-labelled goat anti-porcine IgG was used to detect the captured antibodies. The substrate solution consisted of 0n1 % urea peroxide and 0n02 % 3,3h,5,5h-tetramethyl benzidine, in 10 mM citrate buffer, pH 5n0, mixed in equal volumes ; absorbance values were determined at 450 nm. WB was also performed as previously described using either ORF5-pH protein or sucrose gradient-purified PRRSV as antigen.
Blastogenic transformation test. At regular post-immunization intervals, pigs were treated with xylazine (Bayers) at a dose of 1 mg\kg and blood samples were collected from the anterior vena cava in vacuum tubes containing 1\10 volume 150 mM sodium citrate in PBS, and then diluted 1 : 3 in sterile RPMI. Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Paque (density of 1n077 ; Pharmacia) centrifugation at 1200 g for 20 min. Mononuclear cells were collected from the buffy coat, pelleted and the residual red blood cells were lysed by incubating cells with 0n53 % ammonium chloride for 10 min at 37 mC. After two washes in RPMI, the leukocyte suspension was adjusted to 2i10' cells per ml in RPMI containing 20 % homologous heatinactivated PRRSV-negative porcine serum, 50 U\ml penicillin and 50 µg\ml streptomycin. The antigen-specific proliferation was determined by incubating PBMCs in microtitration plates (4i10& cells in 200 µl\well in triplicate) for 72 h in the presence of various concentrations (0, 0n1, 10 and 25 µg\ml) of ORF5-pH protein. Blastogenic capacity of the PBMCs under test conditions was confirmed by including controls in triplicate containing 2n5, 5 or 10 µg\ml concanavalin A (ConA ; Sigma). After a 72 h stimulation period, the cells were labelled for 18 h with [$H]thymidine (Amersham ; 0n1 µCi\well), harvested with a semi-automatic cell harvester (Skatron Instruments) and the incorporated radiolabelled nucleotide was measured by scintillation counting after addition of a fluorescent liquid scintillator (Cytoscint ; ICN). The level of proliferation was expressed as the mean of counts per minute (CPM) of the test wells minus the mean of the background CPM in control wells. The control for background levels consisted of PBMC cultures in medium alone.
Virus isolation. After collection of blood samples, pigs were euthanized by rapid intravenous injection of sodium pentobarbital (MTC Pharmaceuticals). Specimens were aseptically collected from lungs, spleen, liver, kidneys, and mediastinal and mesenteric lymph nodes. Tissue homogenates were then prepared in DMEM to final concentrations of 1 : 20 and 1 : 100. Following clarification by centrifugation at 10 000 g for 10 min, tissue homogenates were inoculated onto monolayers of MARC-145 cells in 24-well culture plates or PAMs seeded in 96-well microtitration plates. Cells were harvested by two freeze-thaw cycles at 4-5 days p.i. ; tissue culture supernatants were clarified and used for a second passage. Cultures were observed daily for CPE until day 5 p.i. ; infected monolayers were then fixed with cold acetone for IIF.
RT-PCR. Total RNA was extracted from tissues collected from challenged animals and from MARC-145 cells inoculated with tissue homogenates. RT-PCR was performed using oligonucleotide primers 1006PSj1007PR and 1008PSj1009PR to amplify ORF6 and ORF7 genomic regions of PRRSV, respectively, as previously described (Mardassi et al., 1995) .
Histopathological examination. Thin sections (5 µm thick) of formalin-fixed, paraffin-embedded tissues from the lungs, spleen, liver, kidneys, thoracic and mesenteric lymph nodes of all pigs were routinely processed for hematoxylin-phloxin-safran (HPS) staining, as described previously (Dea et al., 1991) .
Results

Transient expression of the cloned ORF5 gene
Expression of the ORF5 product was demonstrated in both COS7 and 293 cells lines at 24 and 36 h post-transfection. The identification of GP & was confirmed by IIF using monospecific anti-ORF5 rabbit antiserum or the porcine anti-PRRSV serum.
As shown in Fig. 1 , an intense cytoplasmic fluorescence could be observed in approximately 10-15 % of the cells and the expressed GP & tended to accumulate near the perinuclear region.
Antibody response of mice and pigs
Sera collected at various times post-immunization (Table 1) were positive for the presence of anti-PRRSV antibodies by IIF. The protein specificity of mouse and pig sera to GP & was established by immunoblotting with purified whole virus and E. coli-expressed recombinant ORF5-pH fusion protein (Fig. 2) and by ELISA (Table 1) . BALB\c mice inoculated with the GST-ORF5 or pRc\CMV5 developed neutralizing antibodies which were first detected 2 weeks after the second booster injection. The VN titres of BALB\c mice sera were estimated between 32 and 64 by week 8 post-immunization and persisted through to the end of the 12 week observation period. In contrast, CD-1 mice did not develop neutralizing antibodies to PRRSV despite a significant anti-ORF5 specific antibody response, detected by ELISA and IIF. Seroconversion was also demonstrated by IIF and ELISA in both groups of vaccinated pigs (Table 1) 15 days after the first injection of either GST-ORF5 or pRc\CMV5. Neutralizing antibodies were detected in sera of the DNA-immunized pigs only 2-3 weeks after the second booster injection (8-9 weeks after first inoculation of plasmidic DNA), and 2 weeks after PRRSV challenge, with estimated titres close to 128. None of the viruschallenged animals in the unvaccinated or GST-ORF5-immunized group developed detectable neutralizing antibodies (VN titres 8) to PRRSV 2 weeks after infection (Table 1) . Control animals were negative for PRRSV and ORF5-pH protein, as determined by IIF and ELISA, throughout the observation period.
Specific blastogenic response to ORF5-pH
PBMCs obtained from both groups of immunized pigs underwent specific blastogenic transformation ex vivo in a dose-dependent manner in the presence of ORF5-pH protein, whereas [$H]thymidine incorporation by the PBMCs obtained from unvaccinated animals remained at basal level (Fig. 3) . Blastogenic transformation indexes of 7-12 and 10-12 were calculated 2 weeks after the second booster injection of GST-ORF5 and pRc\CMV5, respectively. Concentrations higher than 10 µg ORF5-pH protein per ml culture medium did not increase [$H]thymidine incorporation levels in PBMCs from both groups of pigs. No significant variations were observed in the blastogenic response to ConA of vaccinated pigs compared to unvaccinated controls.
Clinical observations
Unvaccinated pigs developed clinical signs of respiratory disease, beginning 2-3 days after virus challenge, which persisted through the end of the 2 week observation period. The principal signs included a marked drop in feed consumption, hyperthermia (40n2-41n7 mC) that persisted for 10-14 days, eyelid oedema, laboured breathing (abdominal respiration) in two pigs accompanied by rasping and crowing sounds heard during inspiration. Apart from a transitory mild fever (39n8-40n4 mC) that lasted not more than 2-3 days, all vaccinated pigs remained clinically healthy during the 2 week observation period following virus challenge. Their average feed consumption and growth rate remained identical to those of unvaccinated, unchallenged controls.
Virus isolation
As summarized in Table 2 , after a single passage on MARC-145 cells, virus was recovered from tissue homogenates (dilutions of 1\20 and 1\100) of several organs (lungs, spleen, kidneys, liver, lymph nodes) from unvaccinated animals 2 weeks after virus challenge, whereas, apart from lungs and mediastinal lymph nodes, no virus was isolated from other organs of DNA-immunized pigs after two successive passages ; this indicates the generalized viraemia of unvaccinated pigs compared to respiratory tract localization of virus in DNAimmunized animals. PRRSV was also recovered from spleen and kidneys of one of the three GST-ORF5-immunized pigs. The presence of the viral genome in the lungs of all three groups of animals could be demonstrated by RT-PCR, but it was only present in the spleen of unvaccinated challenged pigs and those which had been immunized with GST-ORF5. Furthermore, the PRRSV burden was lower in lungs and mediastinal lymph nodes of DNA-vaccinated pigs since it could not be recovered after two passages on MARC-145 cells from the 1\100 dilution of tissue homogenate. The presence of viral antigen could only be detected in the 1\20 dilution of lung and mediastinal lymph nodes homogenates, with delayed appearance of CPEs suggestive of low virus titres.
Necropsy findings
Unvaccinated, virus-challenged pigs euthanized at day 14 p.i. had gross lesions that were confined to the respiratory tract and thoracic cavity. Portions of the lungs were tan in colour and partly collapsed, with occasional anteroventral areas of congestion and consolidation. The mediastinal lymph Table 2 . Virus isolation and RT-PCR analysis performed on day 14 post-challenge j, Virus could be recovered from 1\20 dilution of organ homogenates ; jj, virus could be recovered from 1\100 dilution of organ homogenates ; k, virus could not be recovered. Of the three pigs studied in each case, the number that tested positive is indicated in parentheses.
Virus isolation on MARC-145 cells
Organ Lymph nodes RT-PCR Pig immunized with :
nodes were enlarged and congested. Adherence of the pleura to the thoracic cage was observed in one pig, with slight accumulation of non-suppurative exudate within the thoracic cavity (hydrothorax) and pericardium (hydropericardium). No significant gross lesions were observed in the other organs. Pulmonary hepatization and glandular aspect at lung section was remarkable in one of the GST-ORF5-vaccinated animals. Apart from mild tumefaction of mediastinal lymph nodes in one of the DNA vaccinated pigs, no significant gross abnormalities were observed in this group of animals. Microscopic lesions observed in unvaccinated, virus-challenged pigs were confined to the lungs and consisted of macrophage infiltration, pyknotic cell debris and protein-rich exudate in the lumen of large bronchi and bronchioli, a peribronchiolar and perivascular lymphomononuclear cell infiltration, the presence of lymphomononuclear cells within the alveolar lumen with hyperplasia of type II pneumocytes, mononuclear cell invasion and the presence of pyknotic cells in alveolar septae (Fig. 4 b, c  and d ) . The GST-ORF5-immunized pigs developed intense interstitial pneumonitis, characterized by hyperplasia of bron-chiolar epithelium and pneumocytes type II of the alveolar endothelium, perivascular cuffing, lymphomononuclear cell infiltration and thickening of alveolar septae (Fig. 5 a and b) . A remarkably milder interstitial pneumonitis was observed in the DNA-vaccinated pigs. In those pigs, large airways (bronchi, bronchioli), as well as alveolar ducts, were normal in appearance with absence of cells and cellular debris within the lumen (Fig.  5 c and d ) .
Discussion
In vivo expression of foreign proteins via simple injection of plasmidic DNA into mammals was described in the 1980s (Nicolau et al., 1983 ; Seeger et al., 1984) and a few years later in vivo gene transfer by microprojectiles and particle bombardment was studied (Sanders Williams et al., 1991 ; Yang et al., 1990) . Encouraging results have been also obtained by DNA immunization against viral pathogens and, with few exceptions, laboratory animals such as mice (Davis et al., 1994 ; Martins et al., 1995 ; Ulmer et al., 1993 ; Yokoyama et al., 1995) , guinea-pigs (Bourne et al., 1996) and rabbits (Sundaram et al., 1996) have been generally used as the experimental animals. Only a few experiments have been reported in the literature on DNA immunization in farm animals, including cattle (Cox et al., 1993) , horses (Lunn et al., 1996) , chickens (Fynan et al., 1993) and, more recently, pigs (Gerdts et al., 1997) . Our poor knowledge of the histocompatibility system of farm animals and the difficulties in handling large animals may be discouraging for some investigators.
In this report, DNA immunization was used to evaluate the immunogenicity of a single gene product of a viral pathogen in its natural host. The data obtained demonstrate that the ORF5-encoded GP & of PRRSV elicits neutralizing antibodies in pigs. Furthermore, these experiments suggest that conformational neutralizing epitopes may also be associated with the GP & of PRRSV, since immunizing pigs with the recombinant GST-ORF5 protein failed to trigger the immune system to produce neutralizing antibodies. Indeed, fusion proteins expressed in prokaryotic vectors may not effectively mimic the native viral proteins due to the differences in polypeptide folding, disulfide bond formation or post-translational modifications, notably Nglycosylation. It can therefore be assumed that the induction of neutralizing antibodies in DNA-immunized animals is due to correct glycosylation and post-translational modification of the GP & expressed in host cells. Recently, recombinant adenoviruses carrying the ORF5 gene of PRRSV strain IAFKlop downstream of the CMV promoter were constructed and the ORF5 product that was expressed in human 293 cells was found to be glycosylated and processed in the same way as the native viral protein (Gagnon et al., 1997) .
In the experiments we describe, the development of neutralizing antibodies cannot be attributed to the virus challenge since they were detected in sera of DNA-immunized pigs only and, at 14 days post-challenge, unvaccinated control pigs had no detectable antibodies. Furthermore, previous studies demonstrated that neutralizing antibodies to PRRSV in naturally or experimentally infected pigs start to be detected at low titres as late as 3-4 weeks after exposure to virus (Loemba et al., 1996 ; Nelson et al., 1994 ; Yoon et al., 1995) whereas, in the present study, neutralizing antibodies were detected in sera of DNA-immunized pigs 2-3 weeks after the second booster injection and significant titres of 64-128 were detected 14 days after virus challenge. The appearance of neutralizing antibodies in sera of DNA-immunized, PRRSV-challenged pigs may suggest that virus challenge had a booster effect in developing neutralizing antibodies. This is unlikely since BALB\c mice also developed neutralizing antibodies in the absence of PRRSV challenge.
Neutralizing antibodies in GST-ORF5-immunized BALB\c mice can be attributed to the relatively high quantities of antigen used for immunizing mice compared to that used in pigs (50 µg per mouse versus 300 µg per pig). An alternative interpretation of these results may be that CD-1 mice and pigs are tolerant to the linear epitopes of the E. coli-expressed ORF5-encoded recombinant protein, since CD-1 mice and pigs immunized with GST-ORF5 failed to develop neutralizing antibodies to PRRSV (Table 1 ). The lower titres of anti-GP & antibodies in DNA-immunized mice and pigs compared to the GST-ORF5-immunized animals can be explained by the fact that the injected antigens are available to the B cells and other antigen-presenting cells which can potentially stimulate a strong antibody response. On the contrary, the expressed protein may be retained within the DNA recipient cells and released in smaller amounts into the extracellular space, either by secretion or cell death as a result of cytotoxic protein accumulation. It was previously established that the GP & of PRRSV has an apoptotic effect on transfected cells (Sua! rez et al., 1996) . Previous studies indicate that most proteins eliciting high antibody response after DNA immunization are membrane-associated or secreted proteins (Bourne et al., 1996 ; Davis et al., 1994 ; Fynan et al., 1993 ; Ulmer et al., 1993) . While GP & is a membrane-associated viral glycoprotein, it retains a perinuclear location within the mammalian cells in transient expression experiments (Fig. 1) .
Previous studies have established that protection due to DNA immunization is mediated by both CD4 + and CD8 + T lymphocytes (Doolan et al., 1996 ; Manickan et al., 1995) . According to experimental data on mice, the type of immune response also depends on the route of DNA immunization. It has been previously demonstrated that intradermal immunization can induce very high levels of cytotoxic T lymphocytes mediated by a Th2-like response, whereas intramuscular DNA inoculation favours a Th1-like response (Pertmer et al., 1996 ; Yokoyama et al., 1997) . Since such data are not yet available for large animal models, we used the two inoculation routes simultaneously in order to enhance both types of immune response. In the present study, proliferation assays of PBMCs from pRc\CMV5-and GST-ORF5-immunized pigs showed a specific blastogenesis following stimulation by the recombinant ORF5-pH protein, independent from the production of specific anti-PRRSV neutralizing antibodies. Since the identity of PBMC subpopulation(s) which underwent blastogenesis following antigenic stimulation was not determined, it can be suggested that antigen-specific proliferation may be due to CD4 + and B cell effector cells implicated in eliciting an antibody response. Our results showed that DNA immunization with a plasmid encoding the GP & of PRRSV protected pigs from developing the intensive PRRSV-induced lesions observed in unvaccinated virus-challenged controls. Virus dissemination to organs other than the lungs and the accessory lymph nodes was not observed in DNA-vaccinated animals, even after a massive virus challenge, and these animals had a remarkably lower virus burden in their respiratory system compared to the GST-ORF5 vaccinated or unvaccinated controls. Therefore, it appears that ORF5 may be a good candidate for a subunit recombinant-type vaccine against PRRSV. However, the genomic variabilities of the ORF5 genes which have been recently reported amongst North American field isolates (Meng et al., 1995 ; and between North American and European strains (Mardassi et al., 1995 ; Murtaugh et al., 1995) , need further investigation in order to determine their significance in terms of the antigenic determinants involved in protection.
As expected, DNA immunization was not sufficient to inhibit virus persistence and shedding in the respiratory tract during the short 14 day observation period after virus challenge. However, considering the high challenge dose used in our experiments, the protection conferred to the DNAvaccinated pigs was quite remarkable. Other investigators have reported similar results in connection with post-challenge virus persistence in DNA-immunized animals (Bourne et al., 1996 ; Cox et al., 1993 ; Martins et al., 1995 ; Ulmer et al., 1993) . Mucosal immunity is believed to play a role in protection against PRRSV infection, virus persistence and shedding but this aspect of immunity against PRRSV has not been investigated so far.
Finally, the intensive interstitial pneumonia observed in GST-ORF5-immunized animals could be attributed to the antibody-dependent enhancement (ADE) phenomenon which has been reported to occur in PRRSV-infected pigs (Yoon et al., 1997) . According to the results obtained by these investigators, subneutralizing levels of anti-PRRSV antibodies have the potential to intensify pathogenesis of PRRSV infection due to ADE, but virus replication is significantly inhibited in the presence of neutralizing antibody titres. The immunoglobulins used in passive immunization studies to demonstrate the occurrence of ADE in PRRSV-infected pigs were extracted from polyclonal pig convalescent sera, but results from immunoblotting studies suggested that the ADE was mediated by antibodies specific to the GP & (Yoon et al., 1997) . The intensity of the lymphomononuclear cell infiltration observed in the lungs of GST-ORF5-immunized pigs which failed to develop neutralizing antibodies to the GP & may also suggest that subneutralizing anti-GP & antibodies contribute to ADE of PRRSV infection or, alternatively, the enhanced local secretion of inflammatory cytokines in this group of animals.
